Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

with Guardant subsequently introducing Guardant Reveal (recurrence monitoring) in 2021 and its SHIELD asymptomatic cancer screening solution in 2024. The company's product portfolio also includes ...

​Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents.

The company made strides in gaining regulatory approvals, including Medicare coverage for its Guardant Reveal Smart Liquid Biopsy, a platform for colorectal cancer surveillance. Strategic ...

"Last month, we were pleased to receive Medicare reimbursement for Guardant Reveal in the CRC surveillance setting, which was an important milestone for our MRD business. We are entering 2025 with ...

In 2021, Guardant received US regulatory approval for its MRD test, Reveal, in CRC, and in January 2025 it received Medicare coverage for CRC surveillance, a key indication. We think the MRD ...

“Last month, we were pleased to receive Medicare reimbursement for Guardant Reveal in the CRC surveillance setting, which was an important milestone for our MRD business. We are entering 2025 ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with ...

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with expanded ...